Sonya Reid - Concepedia

Author

Sonya Reid

Vanderbilt University Medical Center ORCID

Also Known As

Balko, Justin M, Choueiri, Toni K., Low, Siew-Kee, Makumbi, Timothy, Roberson, Mya L., S. Reid, Sonya A Reid, Sonya A. Reid, Sonya Reid, Sonya Reid-Lawrence

130

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Emory University Vanderbilt University University of Kansas Medical Center Dana-Farber Cancer Institute

About

Sonya Reid is an author at Vanderbilt University Medical Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	361
2	Public Health	5	5	185
3	Health Sciences	2	2	87
4	Nursing	2	2	77
5	Education	1	1	13

Sonya Reid

Publications

Citations

H-Index

Page 1

	Year	Citations
A Population-Based Study of Genes Previously Implicated in Breast Cancer Chunling Hu, Steven N. Hart, Rohan Gnanaolivu, New England Journal of Medicine	2021	804
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, JAMA Oncology	2021	184
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan, Journal of Clinical Oncology	2023	169
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Erica L. Mayer, Yue Ren, Nikhil Wagle, Journal of Clinical Oncology	2024	95
Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i>, and <i>PALB2</i> Pathogenic Variants Kathryn P. Lowry, H. Amarens Geuzinge, Natasha K. Stout, JAMA Oncology	2022	82
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan, Journal of Clinical Oncology Breast OncologyCancer ManagementPharmacotherapyCdk 4/6IMaintain Trial	2022	73
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer Julie Fu, Sonya Reid, Benjamin French, JAMA Network Open	2022	70
Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer Sonya Reid, Sydney Cadiz, Tuya Pal Current Breast Cancer Reports NursingFamily MedicineGenetic TestingBreast OncologyGenetic Epidemiology	2020	64
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 Ziad Bakouny, Chris Labaki, Punita Grover, JAMA Oncology	2022	62
Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer Erica L. Mayer, Yue Ren, Nikhil Wagle, Cancer Research Prior Cdk4/6iBreast OncologyGs3-06 PalbociclibEndocrine-related CancerEndocrine Oncology	2023	57

Page 1